Cantargia: Phase I safety evaluation part of CANFOUR trial of antibody CAN04 completed and phase IIa part being initiated
Cantargia AB (publ) today announces that all patients in the phase I part of the CANFOUR clinical trial have completed the formal safety evaluation phase of the trial. No dose limiting toxicities (DLTs) were reported at the highest dose level investigated, 10 mg/kg. According to the study protocol, the patients continue CAN04 (nidanilimab) treatment for biomarker and efficacy evaluation. Based on the positive outcome of the phase I safety evaluation, the phase IIa part of the trial can be started as planned.Cantargia is developing the antibody CAN04 for treatment of cancer. The ongoing